Overview
Sepsis is a systemic inflammatory response to an infection and is responsible for nearly one-third of all foal mortality. Current treatment consists of broad-spectrum antibiotics, IV fluids, nutritional support, and administration of other medicines as the situation demands. Survival rates vary depending on the underlying cause of the disease and range from 26-86% for septic neonatal foals, with the majority of studies showing a rate of 45-60%1, 2.
The current invention, a small molecule that targets inflammation associated with Toll-like receptor overexpression, is able to protect horses from endotoxic shock.
Commercial Application
5-phenylmethimazole, or “C10,” is envisioned as the new gold standard therapy for horses that develop sepsis. Based on the individual patient, C10 may be administered alone or in combination with supportive antibiotics, fluids, and other anti-inflammatories. The data generated using an equine model of endotoxic shock (as described in issued US Patent 9,326,972) indicate that C10 is both an effective prophylactic for animals at risk for developing endotoxic shock, as well as a treatment able to rescue those already suffering from the disease3.
Benefits
References
1 The Merck Veterinary Manual. Veterinary Professionals. Management and Nutrition. Management of the Neonate. Sepsis in Foals.
2 Taylor, S. (2015), A review of equine sepsis. Equine Veterinary Education, 27: 99-109.
3 US Patent 9,326,972, issued May 3, 2016.
Photo of mare and foal obtained from Google Images.
Issued Patents
9,326,972
Printable Overview